Novel Drug Delivery Systems Market Report 2025

The novel drug delivery systems market size has grown rapidly in recent years. It will grow from $106.95 billion in 2024 to $117.66 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth during the historic period can be linked to the increasing prevalence of chronic diseases, an expanding geriatric population, rising demand for minimally invasive treatments, heightened patient awareness about drug efficacy and safety, and the development of global healthcare infrastructure.

The novel drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $171.02 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth projected for the forecast period can be attributed to a heightened global emphasis on pandemic preparedness, increased demand for rapid and targeted drug delivery, greater awareness of antimicrobial stewardship, stricter environmental and packaging regulations favoring controlled delivery methods, and expanding public-private partnerships in pharmaceutical innovation. Key trends during this period include the incorporation of nanocarriers and nanoemulsions, development of biodegradable and stimuli-responsive materials, wider use of 3D printing for personalized dosage forms, advancements in transdermal and microneedle technologies, and the adoption of artificial intelligence in formulation design.

The increasing cases of neurological disorders are anticipated to drive growth in the novel drug delivery systems market. Neurological disorders like stroke involve the sudden loss of neurological function caused by interrupted blood flow to the brain, either through a blockage (ischemic stroke) or a blood vessel rupture (hemorrhagic stroke), resulting in brain damage and possible long-term impairments in cognition, sensation, or movement. Factors such as aging populations, the rising prevalence of lifestyle-related conditions including hypertension, diabetes, and obesity, as well as greater exposure to chronic stress and environmental risks, are contributing to the increase in neurological disorders. Novel drug delivery systems aid in treating these disorders by providing targeted and controlled delivery of medications across the blood-brain barrier. For example, in November 2024, the National Health Service (NHS) England reported that stroke admissions in England reached 111,137 in 2023/24, with the highest rise seen in the 50-59 age group, which had 12,533 new cases. Consequently, the growing incidence of neurological disorders is fueling the novel drug delivery systems market.

Leading companies in the novel drug delivery systems market are innovating with products like oral thin films to improve patient compliance and treatment effectiveness. Oral thin films are rapidly dissolving strips applied inside the mouth that deliver drugs directly into the bloodstream through the mucosal lining. For example, in February 2024, CD Formulation, a US pharmaceutical formulation company, introduced Oral Thin Film Technology. This technology enables quick drug absorption by bypassing the gastrointestinal tract and liver metabolism, making it ideal for patients who have difficulty swallowing. It also allows precise dosing and faster onset of effects, enhancing treatment accuracy and convenience across multiple therapies.

In April 2023, DifGen Pharmaceuticals LLC, a US-based pharmaceutical firm, acquired Aveva Drug Delivery Services Inc. for an undisclosed sum. This acquisition is intended to expand DifGen’s expertise in complex dosage forms by adding US research and manufacturing capabilities for transdermal and thin film drug delivery systems. Aveva Drug Delivery Services Inc. specializes in transdermal drug delivery and oral dissolvable films.

Major players in the novel drug delivery systems market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC (GSK), Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Regeneron Pharmaceuticals, Samyang Holdings Corporation, and Galen Limited.

North America was the largest region in the novel drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in novel drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the novel drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The novel drug delivery systems market consists of sales of implants, micelles, exosomes, prodrugs, nasal drug delivery devices, buccal drug delivery films, and ocular drug delivery inserts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The novel drug delivery systems market research report is one of a series of new reports that provides novel drug delivery systems market statistics, including novel drug delivery systems industry global market size, regional shares, competitors with a novel drug delivery systems market share, detailed novel drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the novel drug delivery systems industry. This novel drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Novel drug delivery systems are advanced pharmaceutical technologies aimed at improving the effectiveness, safety, bioavailability, and targeted delivery of medications by precisely controlling the rate, timing, and location of drug release in the body. These systems address the shortcomings of traditional delivery methods, enhance treatment outcomes, and boost patient adherence across diverse medical and therapeutic fields.

Key formulation types within novel drug delivery systems include liposomes, nanoparticles, microspheres, hydrogels, and dendrimers. Liposomes are spherical vesicles made of phospholipid bilayers that encapsulate drugs, allowing for targeted delivery, controlled release, and minimized drug toxicity. The delivery modes include targeted, controlled, and modulated drug delivery systems, which are administered through various routes such as oral, injectable, pulmonary, transdermal, and others. These systems are applied in multiple therapeutic areas including cancer, cardiovascular diseases, neurological disorders, infectious diseases, and autoimmune diseases, serving end-users like hospitals, specialty clinics, research centers, and more.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.